Company profilePharmaceutical#869 of 1,318 in Pakistan✓ No DRAP alerts

Hoffmann Human Health Pakistan Ltd. DSL: 05-352-0065-013785D

Pharmaceutical company · 7 brands · 18 molecules

Ranked #15 of 15 companies in Immunosuppressants

7 registered products 13 pharmaceutical brands 18 distinct molecules 0 DRAP alerts

Company overview

7
registered products
13
pharmaceutical brands
18
distinct molecules
2
therapeutic classes
0
DRAP alerts

Hoffmann Human Health Pakistan Ltd. DSL: 05-352-0065-013785D is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 7 product registrations across 18 distinct molecules. Its portfolio is concentrated in Immunosuppressants and Cardiac Therapy. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by Hoffmann

11 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

11
ceilings with an approval date
0
not revised in 2+ years
2025
oldest approval year
202510
20261

Top molecules by brand count

Cyclosporine ...... 100 Mg2 brands
Cyclosporine ...... 250 Mg1 brand
Dobutamine1 brand
Dobutamine ...... 250 Mg1 brand
Lignocaine Injection ...... 1% %1 brand
Iohexol ...... 647Mg1 brand
Iohexol ...... 755Mg1 brand
Purified Hepatitis-B Surface Antigen ...... 20 Mcg1 brand

Therapeutic classes

Immunosuppressants · 1Cardiac Therapy · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official16 products · Rs 1,041.71 – Rs 26,382.49
Median across source: Rs 4,255.24

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

VALOR PHARMACEUTICALS holds 159 molecules not in this portfolio
000 I.UAcetylcysteineAcitretinAcyclovirAdapaleneAdaplene
BIO LABS (PVT) LTD. holds 139 molecules not in this portfolio
000 I.UAmlodipineAprepitantAremetherArtemetherArtesunate
ALLMED LABORATORIES holds 63 molecules not in this portfolio
AlbuterolArtemetherArtesunateAscorbic AcidAzithromycinCalcium

Get the full profile for Hoffmann

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.